Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg induces significant weight loss (average 14.9% body weight) in non-diabetic adults with overweight or obesity compared to placebo.
If you have obesity and do not have diabetes, a once-weekly injection of semaglutide (2.4 mg) is a highly effective medical treatment that can lead to an average 15% reduction in body weight over 16 months. This is significantly more effective than placebo and addresses the biological drive to regain weight that often limits lifestyle changes alone.
Participants receiving semaglutide lost an average of 14.9% of body weight, compared to 2.4% in the placebo group over 68 weeks.
Why this rating
Based on large-scale, double-blind, randomized controlled trials (STEP 1).
Source
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Stefan D. Anker et al. · International Journal of Cardiovascular Sciences · 2026
DOI 10.36660/ijcs.20260056
More from this paper
- Targeting obesity with GLP-1-based therapies reduces major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity, even without diabetes.Strong
- Lifestyle interventions involving ≥150 minutes of exercise per week combined with caloric restriction are associated with the highest odds of long-term weight loss maintenance (5-10%).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →